ATE269070T1 - Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose - Google Patents

Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose

Info

Publication number
ATE269070T1
ATE269070T1 AT97202644T AT97202644T ATE269070T1 AT E269070 T1 ATE269070 T1 AT E269070T1 AT 97202644 T AT97202644 T AT 97202644T AT 97202644 T AT97202644 T AT 97202644T AT E269070 T1 ATE269070 T1 AT E269070T1
Authority
AT
Austria
Prior art keywords
fibrosis
trichostatin
histone
collagens
decarboxylase inhibitors
Prior art date
Application number
AT97202644T
Other languages
English (en)
Inventor
Albert Emmanuel Corneil Geerts
Toshiro Niki
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Application granted granted Critical
Publication of ATE269070T1 publication Critical patent/ATE269070T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97202644T 1996-09-04 1997-08-29 Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose ATE269070T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96202460A EP0827742A1 (de) 1996-09-04 1996-09-04 Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose

Publications (1)

Publication Number Publication Date
ATE269070T1 true ATE269070T1 (de) 2004-07-15

Family

ID=8224350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97202644T ATE269070T1 (de) 1996-09-04 1997-08-29 Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose

Country Status (8)

Country Link
US (1) US5993845A (de)
EP (2) EP0827742A1 (de)
JP (1) JPH10114681A (de)
AT (1) ATE269070T1 (de)
DE (1) DE69729517D1 (de)
DK (1) DK0827743T3 (de)
ES (1) ES2218638T3 (de)
PT (1) PT827743E (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
EP1129175A2 (de) * 1998-10-16 2001-09-05 Novartis AG Förderung der selbsterneuerungsaktivität und verbesserte gentransduktion in hematopoietischen stammzellen durch inhibierung des histon-deacetylases
DK1140969T3 (da) * 1998-12-14 2007-09-17 Univ Miami Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
US6518012B1 (en) 1999-04-02 2003-02-11 Health Research, Inc. Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
US6449625B1 (en) * 1999-04-20 2002-09-10 Lucent Technologies Inc. Use of a two-way stack approach to optimize flash memory management for embedded database systems
RS50086B (sr) * 1999-04-22 2009-01-22 Biogen Idec Ma Inc., Upotreba antagonista subjedinica alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze
CA2369560C (en) 1999-04-27 2011-02-01 Makoto Nakamuta Agent for prophylaxis and treatment of liver disease
EP1233958B1 (de) 1999-11-23 2011-06-29 MethylGene Inc. Inhibitoren für histone-deacetylase
US6544957B2 (en) 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
US7078045B2 (en) * 2000-03-02 2006-07-18 Sang-Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
WO2001076604A1 (en) * 2000-04-07 2001-10-18 Sang Geon Kim Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
US7256042B2 (en) 2000-04-27 2007-08-14 Geron Corporation Process for making hepatocytes from pluripotent stem cells
US7282366B2 (en) 2000-04-27 2007-10-16 Geron Corporation Hepatocytes for therapy and drug screening made from embryonic stem cells
US7473555B2 (en) 2000-04-27 2009-01-06 Geron Corporation Protocols for making hepatocytes from embryonic stem cells
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AU9013101A (en) 2000-09-29 2002-04-22 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
DE60113645T2 (de) * 2001-04-10 2006-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
WO2002098405A1 (fr) * 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
AU2002348474A1 (en) 2001-10-18 2003-04-28 The Salk Institute For Biological Studies Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
AU2002351413A1 (en) * 2001-12-21 2003-07-30 Patrick Bruggeman Method of obtaining purified enterochromaffin cells and methods of using same
AU2003219803B8 (en) * 2002-02-15 2005-08-25 Sloan-Kettering Institute For Cancer Research Method of treating TRX mediated diseases
AU2005227400B2 (en) * 2002-02-15 2008-04-03 Sloan-Kettering Institute For Cancer Research Method of Treating TRX Mediated Diseases
US7501417B2 (en) 2002-03-13 2009-03-10 Janssen Pharmaceutica, N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
DK1485348T3 (da) 2002-03-13 2008-09-29 Janssen Pharmaceutica Nv Carbonylamino-derivater som nye inhibitorer af histandeacetylase
PL214279B1 (pl) 2002-03-13 2013-07-31 Janssen Pharmaceutica Nv Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
DE60320957D1 (en) 2002-03-13 2008-06-26 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase-inhibitoren
AU2003218735B2 (en) 2002-03-13 2009-03-12 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
CA2479906C (en) 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
JP4804004B2 (ja) * 2002-08-20 2011-10-26 アステラス製薬株式会社 関節軟骨細胞外マトリクス分解阻害剤
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP4612621B2 (ja) 2003-01-17 2011-01-12 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのエステル又はケトン結合を含むカルバミン酸化合物
JP4790594B2 (ja) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
US20050058611A1 (en) * 2003-08-22 2005-03-17 L'oreal Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
WO2005059167A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for identifying histone deacetylase inhibitors
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
ATE400261T1 (de) * 2004-03-11 2008-07-15 Asan Lab Company Cayman Ltd Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie
US20080227868A1 (en) * 2004-03-26 2008-09-18 Volker Schehlmann Composition Comprising an Hdac Inhibitor in Combination with a Retinoid
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
ME01058B (me) 2004-07-28 2012-10-20 Janssen Pharmaceutica Nv Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
EP1824831A2 (de) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
AU2006210746B2 (en) 2005-02-03 2012-04-26 Topotarget Uk Limited Combination therapies using HDAC inhibitors
WO2006088949A1 (en) 2005-02-14 2006-08-24 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
UA99810C2 (ru) 2005-05-13 2012-10-10 Топотаргет Юк Лимитед Фармацевтические составы, которые содержат ингибиторы деацетилазы гистонов
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
BRPI0613429A2 (pt) 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
AU2006307918B2 (en) 2005-10-27 2012-06-21 Janssen Pharmaceutica N.V. Squaric acid derivatives as inhibitors of histone deacetylase
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
AU2007206950B2 (en) 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
JP5137848B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
CN101370791B (zh) 2006-01-19 2012-05-02 詹森药业有限公司 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
JP5225104B2 (ja) 2006-01-19 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
GB2453074B (en) 2006-06-02 2011-06-22 Geron Corp Differentiation of primate pluripotent cells to hepatocyte-lineage cells
EP2073807A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN101868446A (zh) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
ES2395347T3 (es) 2008-03-27 2013-02-12 Janssen Pharmaceutica, N.V. Derivados de indolilalquilamino sustituidos con aza-biciclohexilo como inhibidores novedosos de histona desacetilasa
MD4458C1 (ro) * 2014-06-19 2017-08-31 Мария ДАНУ Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674898A (en) * 1990-03-05 1997-10-07 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis

Also Published As

Publication number Publication date
PT827743E (pt) 2004-08-31
EP0827743B1 (de) 2004-06-16
JPH10114681A (ja) 1998-05-06
DK0827743T3 (da) 2004-10-11
US5993845A (en) 1999-11-30
EP0827742A1 (de) 1998-03-11
EP0827743A1 (de) 1998-03-11
DE69729517D1 (de) 2004-07-22
ES2218638T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
ATE269070T1 (de) Verwendung von histondecarboxylase-hemmern zur behandlung der fibrose
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69831566T2 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE69523745D1 (de) Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
ATE177949T1 (de) Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
BR0116832A (pt) Produto desodorante, método cosmético e método de fabricação de composição desodorante
MXPA05010782A (es) Nuevos hidroxamatos como agentees terapeuticos.
HK1051539A1 (en) Benzamides and related inhibitors of factor xa
ATE369871T1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
KR960705843A (ko) 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)
EA199800690A1 (ru) Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот
ATE215366T1 (de) 3-benzoylphenylessigsäure-derivate enthaltende topische zusammensetzungen zur behandlung der ophthalmischen entzündungserkrankungen
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
ATE442141T1 (de) Verfahren zur behandlung von stoffwechselerkrankungen mit malonyl-coa- decarboxylase-hemmern
DE69512589D1 (de) Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE281831T1 (de) Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties